Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Global Osteoporosis Market is Expected to Attain a Market Size of USD 6.8 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015

January 31, 2012

ALBANY, New York, January 31, 2012 /PRNewswire/ –

According to a new report published by Transparency Market Research (
http://www.transparencymarketresearch.com) “Osteoporosis Drug Market- Global and China
market analysis, size, trends and forecast (2010-2015)
[http://www.transparencymarketresearch.com/osteoporosis-drug-market.html ]” Global
Osteoporosis Market is estimated to be USD 7.3 billion in 2010 and expected to reach USD
11.4 billion in 2015 at a CAGR of 9.2% over the period 2010 to 2015. Bisphosphonate
segment accounted for the largest share at 62.0% of weight management market in 2010.
China Osteoporosis market will be worth USD 2.5 billion in 2015.

Browse full report at:

http://www.transparencymarketresearch.com/osteoporosis-drug-market.html

In 2009, the Global Osteoporosis Drug Market
[http://www.transparencymarketresearch.com/osteoporosis-drug-market.html ] was worth USD
6.8 billion, with Bisphosphonate class of drugs leading the market. In the overall
Bisphosphonate, ibandronate (Bonviva/Boniva; Roche) and zoledronate (Aclasta/Zometa;
Novartis) accounted healthy market share and showed an average sales growth rate of about
of 20% in the past 2 years.

Amgen’s Denosumab is the recent entrant to the Osteoporosis treatment market,
following its approval from the U.S. and European Union (also approved for bone loss
associated with prostate cancer). Denosumab is expected to compete directly with the
Bisphosphonate drug class. However, initial uptake of Denosumab is likely to be as
second-line therapy, mostly in patients who are intolerant to Bisphosphonate. In addition
to the treatment of Osteoporosis, there is substantial potential for Denosumab for
treating bone loss in patients with cancer. Denosumab market is expected to reach USD 3.8
billion in 2015.

Our research indicates that the Osteoporosis drug pipeline is going strong with
various phases of clinical development. Phase III has first-in-class products such as
odanacatib, which possess a novel mechanism of action to combat Osteoporosis. Aprela is
another drug in the stage of development.

The Chinese Osteoporosis drug market
[http://www.transparencymarketresearch.com/osteoporosis-drug-market.html ] is expected to
grow at a CAGR of 13.5% from 2010 to 2015. Increased prevalence of Osteoporosis among
Chinese female population is the principal growth driver of the Osteoporosis drug market.
The other key growth drivers for Chinese Osteoporosis market include increasing elderly
aged population, rising living standards of the Chinese people and increasing awareness
and bone health education.

To gain a competitive advantage, market players should develop cost-competitive drugs
with easy dosage pattern, which promote bone building effectively. Large numbers of
patients are unable to comply with the strict dosage schedule of traditional Osteoporosis
drugs. Further research and development can address the unmet need by coming up with drugs
that have a convenient dosage schedule with better efficacy and safety compared to
traditional treatment of Osteoporosis.

This report provides in-depth analysis of global and China Osteoporosis Market
[http://www.transparencymarketresearch.com/osteoporosis-drug-market.html ] based on
following segmentation:

        - Geographic Markets
             - Global
             - China

        - By Segment
             - Bisphosphonate Drugs
             - SERM Drugs
             - Parathyroid Hormone Drugs
             - Calcitonin Drugs
             - Denosumab Drugs

Related & Recently Published Reports by Transparency Market Research

Weight Loss Market
[http://www.transparencymarketresearch.com/weight-management-market.html ]

Energy Efficient Lighting Technology Market
[http://www.transparencymarketresearch.com/emerging-lighting-technology-market-by-color-temperature.html ]

Energy Efficient Lamps Market
[http://www.transparencymarketresearch.com/latin-america.html ]

Diabetes Devices Market
[http://www.transparencymarketresearch.com/diabetes-devices-market.html ]

Drug Eluting Stents Market
[http://www.transparencymarketresearch.com/coronary-stents-market.html ]

Cardiovascular Devices Market
[http://www.transparencymarketresearch.com/cardiovascular-monitoring-diagnostic-devices-market.html ]

Baby Food Market [http://www.transparencymarketresearch.com/baby-food-market.html ]

Minimally Invasive Surgery Market
[http://www.transparencymarketresearch.com/prostat-cancer-minimal-invasive-surgery-market.html ]

Browse all Pharmaceutical Market
[http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html ] Research
Reports

About Us

Transparency Market Research [http://www.transparencymarketresearch.com ] is a global
market intelligence company, providing global business information reports and services.
Our exclusive blend of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. We are privileged with highly
experienced team of Analysts, Researchers, and Consultants, who use proprietary data
sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts,
so that it always reflects the latest trends and information. With a broad research and
analysis capability, Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research material for business
reports.

        Contact

        Ms Amita
        90 Sate Street, Suite 700
        Albany, NY 12207
        Tel: +1-518-618-1030
        USA - Canada Toll Free: 866-552-3453
        Email: sales@transparencymarketresearch.com

http://www.transparencymarketresearch.com

http://www.twease.org

http://blog.transparencymarketresearch.com

http://transparencymarketresearch.blogspot.com

SOURCE Transparency Market Research


Source: PR Newswire